Welcome, Guest
Username: Password: Remember me
General
  • Page:
  • 1

TOPIC: Barchart article

Barchart article 13 Jan 2014 10:52 #1214

  • fas
  • fas's Avatar Topic Author
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3332
  • Thank you received: 1114
Somebody mailed me the link to this article- nothing special- but anyway- Barchart article

Thanks to new legislation being approved by the Upper House of Japan's Parliament in November, Japan's so-called "drug lag," specifically with respect to regenerative medicine, will likely become a thing of the past. By retooling the framework of the regulatory process for regenerative medicine products, the nation has shifted from a global drug development laggard to one of the most proactive countries on the planet aiming to safely expedite growth in the burgeoning, yet volatile, stem cell industry to meet the needs of a rapidly expanding aging population. The new laws are designed to promote innovation and could provide a clear channel to rapid commercialization that will benefit industry-leading companies like Cellular Dynamics International, Inc. (NASDAQ: ICEL), Athersys, Inc. (NASDAQ: ATHX) and Cytori Therapeutics, Inc. (NASDAQ: CYTX).

Japan's motivations are not clouded; they're concise and essentially borne out of economic necessity. With the second-largest mature healthcare market in the world, the country faces profound challenges, as nearly 20 percent of its population is aged 65 years or more. By 2050, it's estimated that up to 39 percent of Japan's citizens will be older than 65, burdening the government to spend a greater portion of its budget on healthcare and pensions, while the working class contributing taxes contracts proportionately.

Prime Minister Shinzo Abe's partial solution to the problem was to have Japan's Parliament, the Diet, revamp the Pharmaceutical Affairs Law to provide a new definition for medical products containing stem cells and take a bold step to vastly accelerate bringing new regenerative medicine products to market. In short, the traditional pathway of multiple lengthy and expensive stages of clinical trials is no longer mandatory for regenerative medicine therapeutic candidates that qualify under the new framework. Under the new legislation, if small Phase I/II clinical studies can establish product safety and provide a meaningful indication of therapeutic effectiveness, accelerated approval becomes a possibility - in qualifying situations the government will grant conditional approval to commercialize the product. At that point, a post-market surveillance period will be in effect to more thoroughly delineate safety and efficacy profiles, with subsequent final approval granted at a later date, or alternatively, the potential of revocation of the approval if data shows the therapy to be inefficacious or unsafe.

If the new policy can lead to new therapeutics being available and shave the regulatory route from seven-to-ten years down to only two or three years without sacrificing safety, Abe's plan could prove transformational on multiple fronts. The plan incentivizes domestic investment and foreign companies to focus on development efforts in Japan, which has experienced a drop off in biomedical innovation and clinical activity in recent years. These effects could be good for Japanese patients, the national healthcare system, and the Japanese economy. The new framework mandates studies to be conducted on Japanese people, even if in limited numbers, to ensure that any expression of efficacy or side effects are not skewed by non-native genotypes. Even more importantly, bringing new treatments to market to meet areas of unmet medical need could actually lower the cost of healthcare for the government by keeping people healthier and more productive.

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:
  • Page:
  • 1
Time to create page: 0.093 seconds

Copyright Information

Copyright Fas Kuiters © 2016 young-foxes.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.

 

 

Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites